ClinicalTrials.gg
TerminatedNCT01591902Updated Sep 11, 2018

Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®

A Phase 4 interventional study of Tesamorelin and Placebo-Control in Diabetic Retinopathy and HIV, sponsored by Theratechnologies. Terminated at 24 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-09-11.

Sponsored by Theratechnologies · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
129
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 267 studies in Diabetic Retinopathy with a site in United States — 36 open to participants now, 55 under way, 6 of them phase 3. Diabetic Retinopathy · United States.

Enrollment
78th of 196
129 · median 72
Started
2012
with 13 others
Phase 4
20 of 267
6 open now
Registered
78th of 267
by date

Among the 267 studies in Diabetic Retinopathy with a site in United States, this one is the 78th largest by enrollment of the 196 interventional ones that give a count, is one of 14 that started in 2012, is one of 20 in phase 4, and was the 78th registered.

Diabetic Retinopathy

779 studies on the registry are indexed under Diabetic Retinopathy; 143 are open to participants now.

Browse Diabetic Retinopathy studies →

Open to participants now

36 of the 267 studies in Diabetic Retinopathy with a site in United States are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 92 Diabetic Retinopathy studies recruiting now, 60 (65%) set no upper age limit and 10 (11%) stop at 75 or younger; 8 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 267 studies in Diabetic Retinopathy with a site in United States, or all of them as a file.
02

Study summary

To show the non-inferiority of EGRIFTA® vs. placebo in the development or progression of Diabetic Retinopathy in HIV-infected subjects with concomitant abdominal lipohypertrophy and Type 2 diabetes mellitus (T2DM).

Read the detailed description

To date, EGRIFTA® has not been studied for longer than 1 year in human subjects, nor has EGRIFTA® been studied in Type 2 diabetic HIV-infected subjects who are receiving oral hypoglycemic agents, GLP-1 analogues, or insulin. The present study will assess the potential of EGRIFTA® to induce or exacerbate DR in HIV-infected subjects on antiretroviral therapy who have concomitant abdominal lipohypertrophy and T2DM, and explore the long-term effects of EGRIFTA® on glycemic control and major adverse cardiovascular event (MACE) in this population.

03

Conditions studied

  • Diabetic Retinopathy
  • HIV

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject has given written and is willing to comply with the requirements of the protocol;
  2. Subject is an adult man or woman (≥ 18 years old);
  3. Subject has laboratory confirmed infection;
  4. Subject is receiving ART that has been stable for at least 8 weeks prior to screening;
  5. Subject has physical evidence of abdominal lipohypertrophy, as determined by the examining study physician;
  6. Subject has T2DM as determined by previous ≥ 6.5%, previous fasting plasma glucose

    • ≥ 126 mg/dL (7.0 mmol/L), and/or previous 2-hour plasma glucose ≥ 200 mg/dL (11.1 mmol/L) during oral glucose tolerance testing (OGTT), and/or previous random plasma glucose ≥ 200 mg/dL (11.1 mmol/L) with symptoms of uncontrolled DM;
    • if subject has been diagnosed with T2DM and is on glucose lowering medications for greater than 1 year the above glucose parameters do not apply;
  7. Subject, at the time of screening, has HbA1c between 6.0% and 12.0%;
  8. Subject's diabetes has been treated for at least 1 year by diet alone, individuals who are on a stable dose (at least 3 months) of insulin, an OHA, or a GLP-1 analogue plus insulin to control diabetes are permitted if their HbA1C is below 6.0%. OHA, GLP-1 analogue, or OHA/GLP-1 analogue plus insulin according to current American Diabetes Association (ADA) guidelines, and doses have been stable for at least 3 months;
  9. If the subject is using lipid lowering drugs, the dose must be stable for at least 2 months prior to screening;
  10. Subject must have an (ECG) without abnormalities within 6 months prior to screening;
  11. Pre-menopausal women of are eligible only if they are not pregnant (negative urine pregnancy tests at screening and baseline) or lactating and are using an acceptable form of prior to study entry and for at least 2 months after completing treatment. Acceptable contraception is defined as two barrier methods, or one barrier method with a spermicide, or an intrauterine device, or an oral contraceptive;
  12. Women of non-childbearing potential must be (no menses for more than 1 year) or surgically sterile (tubal ligation or hysterectomy);
  13. Women over 40 years old must have a negative mammogram within 6 months prior to screening or a mammogram will be taken at screening;
  14. Men must have a normal prostate exam and a prostate specific antigen (PSA) Individuals who are on a stable dose (at least 3 months) of insulin, less than or equal to 5 ng/mL within 6 months prior to screening or PSA and, for men 50 years of age or older, a prostate specific antigen will be measured at screening

Exclusion criteria

Exclusion Criteria:

  1. Subject has Type 1 DM;
  2. Subject has (BMI) \< 18.5 kg.m2;
  3. Subject has or has had an opportunistic infection or acquired immune deficiency syndrome (AIDS)-defining illness within 3 months of screening;
  4. Subject has or has had a or, for women, personal or family (first degree relative) history of breast cancer. Exceptions are basal cell carcinoma, in situ carcinoma of the cervix, in situ anal carcinoma, treated and stable cutaneous squamous cell carcinoma. and stable Kaposi's sarcoma;
  5. Pre-existing PDR or severe non-PDR (NPDR), defined as an ETDRS level of ≥ 53 in either eye;
  6. Subject has or has had cytomegalovirus (CMV) retinitis, toxoplasmosis, or any other ocular infection that would prevent evaluation of DR;
  7. Subject has previously been treated for DR (treatments such as laser photocoagulation, intravitreal injection, or vitrectomy);
  8. Subject has any of the following illnesses or conditions:

    1. hypopituitarism, history of pituitary tumor or pituitary surgery;
    2. untreated hypothyroidism;
    3. head irradiation or head trauma that has affected the somatotropic axis;
    4. uncontrolled hypertension, defined as systolic pressure > 140 mm Hg and diastolic pressure > 90 mm Hg;
    5. unstable CV condition, defined as:

    i. acute MI; ii. unstable angina; iii. decompensated congestive heart failure (CHF, new onset or exacerbation); iv. stroke; v. history of any of the above within 6 months prior to screening; f. hepatic abnormality, defined as (AST) or alanine aminotransferase (ALT) > 3 times the (3 x ULN); g. renal abnormality, defined as serum creatinine > 2 x ULN; h. lipid metabolism abnormality, defined as fasting triglycerides > 1500 mg/dL; i. anemia, defined as ≤ 7 g/dL;

  9. Drug or hormone use as follows

    1. Men: change in regimen or supraphysiological dose of testosterone within 2 months prior to screening;
    2. anabolic steroids, GH, GH secretagogue, GHRF products or analogs (including EGRIFTA®), IGF-1, or IGF binding protein 3 (IGFBP 3) within 6 months prior to screening;
  10. Drug or alcohol dependence within 6 months prior to screening;
  11. Subject is using or has used anorectics, anorexigenics, or anti-obesity agents within 3 months prior to screening;
  12. Subject is pregnant or nursing;
  13. Other significant disease that, in the Investigator's opinion, would exclude the subject from the trial;
  14. Participation, within 30 days prior to screening, in another clinical trial of an agent that could affect IGF-1 levels;
  15. Known to the study drug treatments.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
129 participants (actual)

Study arms

  • Experimental
    EGRIFTA Treatment Grop

    Sterile, lyophilized, nonpyrogenic powder containing tesamorelin acetate with mannitol as excipient

    Drug: Tesamorelin

  • Placebo comparator
    Placebo

    Placebo-controlled

    Drug: Placebo-Control

Interventions

  • Daily 2 mg subcutaneous injections of tesamorelin

  • DrugPlacebo-Control

    3.0 mL vials

06

What researchers measure

Primary outcomes

  1. Difference in percentages of subjects with a 3-step or greater progression (from both eyes) on the Early Treatment Diabetic Retinopathy Study (ETDRS) PERSON scale.

    Subjects will undergo an opthamologic examination including fundus photographs at 3 month intervals for duration of 36 months

    Time frame: 3 years

Secondary outcomes

  1. Change from baseline in HbA1c by intensification of concomitant diabetic treatment

    HbA1c values will be obtained at screening at month 3, 6, 12, 18, 24, 30 and 36

    Time frame: 3 years

07

Study locations

24 sites
  • Southwest Center for HIV/AIDS
    Phoenix, Arizona 85004, United States
  • Spectrum Medical Group
    Phoenix, Arizona 85012, United States
  • 5P21 Rand Schrader Clinic
    Los Angeles, California 90033, United States
  • University of California CARE Clinic, Los Angeles
    Los Angeles, California 90035, United States
  • Palmtree Clinical Research, Inc.
    Palm Springs, California 92262, United States
  • UCSD Antiviral Research Center
    San Diego, California 92103, United States
  • VAMC, Infectious Disease Section 111W
    San Francisco, California 94121, United States
  • Capital Medical Associates, PC
    Washington, District of Columbia 20036, United States
  • Gary J. Richmond, M.D., PA
    Fort Lauderdale, Florida 33316, United States
  • Orange County Health Department
    Orlando, Florida 32809, United States
  • Triple O Research Institute
    West Palm Beach, Florida 33401, United States
  • Rowan Tree Medical , P.A.
    Wilton Manors, Florida 33305, United States
  • Be Well Medical Center, P.C.
    Berkley, Michigan 48072-3436, United States
  • Southampton Clinical Research, Inc d.b.a. Central West Clinical Research
    Saint Louis, Missouri 63108, United States
  • Southampton Healthcare, Inc.
    Saint Louis, Missouri 63139, United States
  • South Jersey Infectious Disease
    Somers Point, New Jersey 08244, United States
  • Harold Hamm Diabetes Center at the University of Oklahoma
    Oklahoma City, Oklahoma 73104, United States
  • Fanno Creek Clinic, LLC
    Portland, Oregon 97219, United States
  • Central Texas Clinical Research
    Austin, Texas 78705, United States
  • St. Hope Foundation, Inc.
    Bellaire, Texas 77401, United States
  • Dallas VA Medical Center
    Dallas, Texas 75216, United States
  • UT Southwestern Medical Center, Atten: HIV Research Unit
    Dallas, Texas 75235, United States
  • Research Access Network
    Houston, Texas 77098, United States
  • Virginia Mason Medical Center
    Seattle, Washington 98112, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2012 to primary completion in May 2018, 71 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2012
First posted
May 4, 2012
StartActual
Jun 2012
Primary completionActual
May 2018
CompletionActual
Aug 2018
Last update
Sep 11, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 11, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01591902
Lead sponsor
Theratechnologies
Responsible party
Sponsor
First posted
May 4, 2012
Start date
Jun 2012
Primary completion
May 2018
Completion
Aug 2018
Last update
Sep 11, 2018

Study contacts

Marilyn De Chantal

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tesamorelin

Start the discussion